A Phase 2 Study of Nivolumab + BMS-986016 (Relatlimab) in Patients With Metastatic Uveal Melanoma
Latest Information Update: 04 Dec 2023
At a glance
- Drugs Nivolumab (Primary) ; Relatlimab (Primary)
- Indications Uveal melanoma
- Focus Therapeutic Use
- 29 Nov 2023 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.
- 29 Nov 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 04 May 2023 Status changed from recruiting to active, no longer recruiting.